secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001753926-25-000635
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical expands OKV-119 collaboration with Okava to include dogs for metabolic health
--------------------------------------------------------------------------------

- Collaboration expanded to develop OKV-119 (long-acting GLP-1 implant) for dogs for weight management and diabetes.
- Over 50% of U.S. dogs are overweight or obese; leaner dogs can live more than two years longer.
- OKV-119 leverages NanoPortal technology for six-month+ dosing, mimicking fasting effects to improve insulin sensitivity.
- Financial terms not disclosed; partnership minimizes Vivani's costs/risks with upside via milestone payments and royalties.
- Expands prior 2019 collaboration that focused on developing OKV-119 for cats.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625000635/0001753926-25-000635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625000635/vani-20250412.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-000635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer